Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevor-cel in Relapsed/Refractory Multiple Myeloma
NCT03915184Phase 2Active, not recruiting
- Sponsor
- CARsgen Therapeutics
- Start
- Sep 2019
- Primary completion
- Dec 2024
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of zevorcabtagene autoleucel in multiple myeloma (MM), sponsored by CARsgen Therapeutics. Primary endpoints: Incidence of Treatment Related adverse events (AEs), Maximum Tolerated Dose and 1 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
zevorcabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03915184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03915184.